-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the third quarterly report performance forecasts of listed companies are gradually appearing
.
In the raw material medicine industry, relevant companies such as Huahai Pharmaceutical, Boton Co.
, Ltd.
have issued performance forecasts for the first three quarters
.
Among them, Huahai Pharmaceutical released a performance forecast for the first three quarters of 2021 on the evening of October 14.
Decrease by about 20% to 32%
.
Regarding the reasons for the changes in performance, Huahai Pharmaceutical said that during the reporting period, the company’s net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses fell sharply year-on-year, mainly due to the general decline in raw material drug product prices, the decline in the US dollar exchange rate, and product sales.
Multiple factors such as structural changes, rising prices of raw materials, and continuous increase in environmental protection costs have affected the profit of API products.
The US preparation business continues to be affected by the FDA ban and the company's increasing investment in biologics and new drug research and development
.
On October 11, Proton issued an announcement stating that the net profit for the first three quarters is expected to be 347 million yuan-370 million yuan, a year-on-year increase of 45%-55%
.
It is reported that during the reporting period, the company continued to expand and enrich its product pipeline, continuously improve its technical capabilities, product delivery capabilities and order acquisition capabilities, and the level of profitability continued to improve
.
It is worth mentioning that a number of brokerages expressed optimism about the outlook for the API industry
.
Among them, Guohai Securities said that in the long run, China's API industry is one of the core directions of China's new pharmaceutical manufacturing.
It has the dual growth potential of upgrading itself and undertaking the transfer of the global industrial chain, and iteratively develops towards a higher-end innovative drug CDMO.
The logic is clear, the moat continues to improve, the transition from a cyclical industry to a growth industry, and 2020 is a new round of intensive production capacity construction in the API industry.
This year is expected to begin to concentrate on contributing profits.
Therefore, it is optimistic that the API industry will usher in 2021.
Double-click Davis, given the industry recommended rating, we propose a focus on new manufacturing API upgrade (CDMO) logically related to the subject of medicine, such as Provincetown, Jiuzhou Pharmaceutical, Sky shares, the United States and Novartis, medicine and other Aoxiang
.
Zhongtai Securities also issued a research report stating that CRO/CDMO and medical services are the high-prosperity track with broad industry space and continued strong demand, and the value of the pre-adjustment has been highlighted to usher in the rise.
.
The specialty API segment has experienced more than half a year of "transformation investment" and "short-term disturbance" performance fluctuations.
The second half of the year is expected to gradually usher in the inflection point of growth and have a double-click opportunity.
The agency said it continues to be optimistic about the continuation of the structural market of the pharmaceutical sector
.
In addition, some API stocks have also been significantly sought after this year
.
For example, the Sino-European Medical and Health Mixed Fund managed by Gülen bought 8.
72 million shares of Proton in the second quarter of 2020, and increased the position of 9.
64 million shares in the second quarter of 2021
.
As of the second quarter report, the fund was ranked as the fourth largest tradable shareholder of Proton
.
Bo Teng shares rose rapidly on October 13, and quickly rose by more than 8% in the afternoon to report 96.
56 yuan.
The temporary turnover of 485 million yuan has exceeded the previous day's full-day turnover, with a total market value of 52.
3 billion yuan
.
It is understood that due to Q3 performance exceeding expectations, securities firms such as Southwest Securities, Bank of China Securities and other securities firms have rated Boten shares as buy.
The reasons for Southwest Securities’ ratings include: continued high growth in performance, significant and rapid growth in profits, and rapid revenue growth; continued acceleration in production capacity Expansion lays the foundation for high performance growth; the "API + preparation + biological medicine" comprehensive CDMO platform continues to advance, and CDMO for cell and gene therapy is worth looking forward to
.
Bank of China Securities’ rating reasons include: “Extended and endogenous” the company’s operating income and profitability continue to increase; the three major business segments of API CDMO, preparation CDMO, and cell gene therapy CDMO are developing together; capacity expansion, accumulating accumulation
.
.
In the raw material medicine industry, relevant companies such as Huahai Pharmaceutical, Boton Co.
, Ltd.
have issued performance forecasts for the first three quarters
.
Among them, Huahai Pharmaceutical released a performance forecast for the first three quarters of 2021 on the evening of October 14.
Decrease by about 20% to 32%
.
Regarding the reasons for the changes in performance, Huahai Pharmaceutical said that during the reporting period, the company’s net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses fell sharply year-on-year, mainly due to the general decline in raw material drug product prices, the decline in the US dollar exchange rate, and product sales.
Multiple factors such as structural changes, rising prices of raw materials, and continuous increase in environmental protection costs have affected the profit of API products.
The US preparation business continues to be affected by the FDA ban and the company's increasing investment in biologics and new drug research and development
.
On October 11, Proton issued an announcement stating that the net profit for the first three quarters is expected to be 347 million yuan-370 million yuan, a year-on-year increase of 45%-55%
.
It is reported that during the reporting period, the company continued to expand and enrich its product pipeline, continuously improve its technical capabilities, product delivery capabilities and order acquisition capabilities, and the level of profitability continued to improve
.
It is worth mentioning that a number of brokerages expressed optimism about the outlook for the API industry
.
Among them, Guohai Securities said that in the long run, China's API industry is one of the core directions of China's new pharmaceutical manufacturing.
It has the dual growth potential of upgrading itself and undertaking the transfer of the global industrial chain, and iteratively develops towards a higher-end innovative drug CDMO.
The logic is clear, the moat continues to improve, the transition from a cyclical industry to a growth industry, and 2020 is a new round of intensive production capacity construction in the API industry.
This year is expected to begin to concentrate on contributing profits.
Therefore, it is optimistic that the API industry will usher in 2021.
Double-click Davis, given the industry recommended rating, we propose a focus on new manufacturing API upgrade (CDMO) logically related to the subject of medicine, such as Provincetown, Jiuzhou Pharmaceutical, Sky shares, the United States and Novartis, medicine and other Aoxiang
.
Zhongtai Securities also issued a research report stating that CRO/CDMO and medical services are the high-prosperity track with broad industry space and continued strong demand, and the value of the pre-adjustment has been highlighted to usher in the rise.
.
The specialty API segment has experienced more than half a year of "transformation investment" and "short-term disturbance" performance fluctuations.
The second half of the year is expected to gradually usher in the inflection point of growth and have a double-click opportunity.
The agency said it continues to be optimistic about the continuation of the structural market of the pharmaceutical sector
.
In addition, some API stocks have also been significantly sought after this year
.
For example, the Sino-European Medical and Health Mixed Fund managed by Gülen bought 8.
72 million shares of Proton in the second quarter of 2020, and increased the position of 9.
64 million shares in the second quarter of 2021
.
As of the second quarter report, the fund was ranked as the fourth largest tradable shareholder of Proton
.
Bo Teng shares rose rapidly on October 13, and quickly rose by more than 8% in the afternoon to report 96.
56 yuan.
The temporary turnover of 485 million yuan has exceeded the previous day's full-day turnover, with a total market value of 52.
3 billion yuan
.
It is understood that due to Q3 performance exceeding expectations, securities firms such as Southwest Securities, Bank of China Securities and other securities firms have rated Boten shares as buy.
The reasons for Southwest Securities’ ratings include: continued high growth in performance, significant and rapid growth in profits, and rapid revenue growth; continued acceleration in production capacity Expansion lays the foundation for high performance growth; the "API + preparation + biological medicine" comprehensive CDMO platform continues to advance, and CDMO for cell and gene therapy is worth looking forward to
.
Bank of China Securities’ rating reasons include: “Extended and endogenous” the company’s operating income and profitability continue to increase; the three major business segments of API CDMO, preparation CDMO, and cell gene therapy CDMO are developing together; capacity expansion, accumulating accumulation
.
